Posts

The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States.

Biohaven Pharmaceutical Holding Company Ltd said its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.

Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.